Emergent BioSolutions, Inc., to acquire Trubion Pharmaceuticals

Emergent BioSolutions, Inc., of Rockville, Maryland, has announced it will acquire the Seattle-based Trubion Pharmaceuticals, Inc.

“This acquisition strengthens Emergent’s biologics capabilities in two key aspects,” Fuad El-Hibri, chairman of the board of directors and chief executive officer of Emergent BioSolutions, Inc., said. “First, it diversifies our product pipeline beyond infectious diseases into the two high growth areas of oncology and autoimmunity. And, second, it broadens our monoclonal antibody therapeutic capabilities.”

Trubion has two clinical-stage therapeutic candidates. One is a treatment for Rheumatoid arthritis and lupus, the other for non-Hodgkin’s lymphoma and leukemia. Upon completion of the acquisition, Emergent will maintain facilities in Seattle, Washington. The area will become a product site focusing on therapeutics.

“The acquisition of Trubion by Emergent should accelerate the continued development of our leading products and technologies," Steven Gillis, executive chairman of the board of directors and acting president of Trubion, said.

Emergent, best known as the creators of the only FDA approved vaccine for anthrax, closed the deal for $96.8 million and a potential later payment of as much as $38.7 million.

This will be the second major deal for Emergent this week. The biotech announced on August 11 that it has agreed to develop a broad pandemic influenza vaccine with Singapore-based Temasek Life Science Ventures Pte Ltd.